Pathology: Extensive stage SCLC (Es-SCLC) - maintenance (M); Extensive stage SCLC (Es-SCLC) - 1st Line (L1);
| Extensive stage SCLC (Es-SCLC) - maintenance (M) | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | |||||||
| CheckMate 451 (N ; all population), 2019 | CheckMate 451 (NI ; all population), 2019 | IMpower-133, 2018 | CASPIAN (D ; all population), 2019 | CASPIAN (DT ; all population), 2019 | CA184-156, 2016 | KEYNOTE-604, 2020 | ||
| pembrolizumab plus SoC | 1 | T1 | ||||||
| nivolumab alone | 1 | T1 | ||||||
| nivolumab plus ipilimumab | 1 | T1 | ||||||
| durvalumab plus etoposide and platin | 1 | T1 | ||||||
| durvalumab plus tremelimumab plus SoC | 1 | T1 | ||||||
| atezolizumab plus SoC | 1 | T1 | ||||||
| ipilimumab plus SoC | 1 | T1 | ||||||
| placebo | 0 | T0 | T0 | |||||
| etoposide plus platin | 0 | T0 | T0 | |||||
| placebo plus SoC | 0 | T0 | T0 | T0 | ||||